This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490.
Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498–506.
Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 770–790.
Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol 2009; 54: 330–334.
Atalay F, Gulmez O, Ozsancak Ugurlu A . Cardiotoxicity following cyclophosphamidetherapy: a case report. J Med Case Reports 2014; 8: 252.
Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V . Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323–334.
Dadfarmay S, Berkowitz R, Kim B . Irreversible end-stage cardiomyopathy following a single dose of cyclophosphamide. Congest Heart Fail 2012; 18: 234–237.
Senkus E, Jassem J . Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37: 300–311.
Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS et al. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab 2012; 40: 54–63.
Nishikawa T, Miyahara E, Kurauchi K, Watanabe E, Ikawa K, Asaba K et al. Mechanisms of fatal cardiotoxicity following high-dose cyclophosphamide therapy and a method for its prevention. PLoS ONE 2015; 10: e0131394.
Himmel HM . Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds. J Pharmacol Toxicol Methods 2013; 68: 97–111.
Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116–1124.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Martin, M., Fornecker, Lm., Marcellin, L. et al. Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. Bone Marrow Transplant 52, 1674–1677 (2017). https://doi.org/10.1038/bmt.2017.188
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.188
This article is cited by
-
A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2022)
-
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation
Journal of Thrombosis and Thrombolysis (2021)
-
Cyclophosphamide
Reactions Weekly (2018)